查詢結果分析
相關文獻
- 慢性阻塞性肺病藥物治療新趨勢--長效型支氣管擴張吸入劑
- 腹直肌鞘血腫合併慢性阻塞性肺病: 病例報告
- Lung Volume Reduction Surgery--A Case Report
- Ariflo[fef0]--A Brief Report on a New Second-Generation Phosphodiesterase 4 Inhibitor
- Acute Chronic Respiratory Failure Complicated by Undetected Obstructive Sleep Apnea Syndrome
- 護理一位慢性阻塞性肺病個案之經驗
- 慢性阻塞性肺病的復健工作
- A Multidisciplinary Pulmonary Rehabilitation Program for Patients with Moderately Severe Chronic Obstructive Pulmonary Disease
- Agrobacterium Radiobacter Bacteremia in a Patient with Chronic Obstructive Pulmonary Disease
- 硫酸鎂注射在於治療慢性阻塞性肺病併急性發作的功效
頁籤選單縮合
題 名 | 慢性阻塞性肺病藥物治療新趨勢--長效型支氣管擴張吸入劑=A New Era of Therapeutic Strategies for Chronic Obstructive Pulmonary Disease--Long-acting Bronchodilator Inhalers |
---|---|
作 者 | 盧慶祥; 蕭詩如; 吳企華; | 書刊名 | 內科學誌 |
卷 期 | 28:2 2017.04[民106.04] |
頁 次 | 頁59-64 |
分類號 | 418.263 |
關鍵詞 | 慢性阻塞性肺病; 長效型乙二型交感神經刺激劑; 長效型抗膽鹼劑; Chronic obstructive pulmonary disease; COPD; Long-acting β₂ sympathomimetic agonists; LABA; Long-acting muscarinic antagonists; LAMA; |
語 文 | 中文(Chinese) |
中文摘要 | 慢性阻塞性肺病(Chronic obstructive pulmonary disease,COPD) 是常見且容易導致死亡的呼吸道疾病,吸入型支氣管擴張劑是治療COPD 患者主要藥物。近年來新型長效型乙二型交感神經刺激劑和長效型抗膽鹼藥物陸續研發,臨床上也證實可有效改善COPD 症狀及肺功能,且無明顯副作用,只要一天一次,更方便的給藥。因此目前在2017 年GOLD 指引,對於穩定型COPD 患者,建議使用長效劑型支氣管擴張劑。 |
英文摘要 | Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality in pulmonary diseases worldwide. Inhaled bronchodilators are the main therapeutic agents for COPD. Long-acting muscarinic antagonists and long-acting β_2 sympathomimetic agonists have been developed in recent years. These agents have been proven to improve COPD symptoms and pulmonary functions. They have no significant adverse effects. The once-daily dosing is also more convenient for patients. Both agents are now recommended by the GOLD Strategy as a mainstay treatment for stable COPD patients. |
本系統中英文摘要資訊取自各篇刊載內容。